Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults

Trial Profile

A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VIB-4920 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 19 Oct 2018 According to a Viela Bio media release, data from this trial will be presented at the 2018 American College of Rheumatology / Association of Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting (October 2018).
    • 17 Jun 2017 Results assessing the safety, pharmacokinetics, pharmacodynamics, and immunogenicity presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 18 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top